Diabetes as a procoagulant condition

[1]  A. Hingorani,et al.  Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vasculo-Protective Action of Aspirin , 2002, Circulation.

[2]  G. Paolisso,et al.  Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. , 2002, Journal of the American College of Cardiology.

[3]  Y. Aso,et al.  Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. , 2002, Metabolism: clinical and experimental.

[4]  J. Colwell.  Treatment for the procoagulant state in type 2 diabetes. , 2001, Endocrinology and metabolism clinics of North America.

[5]  D. Bruttomesso,et al.  Insulin infusion normalizes fasting and post‐prandial albumin and fibrinogen synthesis in Type 1 diabetes mellitus , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[6]  M. Konieczkowski,et al.  Increased synthesis of thromboxane A(2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  H. Saito,et al.  Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. , 2001, Atherosclerosis.

[8]  S. Martin,et al.  Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice. , 2001, Journal of autoimmunity.

[9]  G. Pellegrini,et al.  Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[10]  M. Lorenzi,et al.  Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. , 2001, Diabetes.

[11]  R. Gleason,et al.  Fibrinogen and factor VII levels improve with glycemic control in patients with type 1 diabetes mellitus who have microvascular complications. , 2001, Archives of internal medicine.

[12]  M. Nishikawa,et al.  Significance of chemokines and activated platelets in patients with diabetes , 2000, Clinical and experimental immunology.

[13]  P. Grant,et al.  Plasminogen-activator inhibitor type 1 and coronary artery disease. , 2000, The New England journal of medicine.

[14]  G. Paolisso,et al.  Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. , 2000, Circulation.

[15]  K. Tokunaga,et al.  Elevation of fibrinogen and thrombin-antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. , 2000, Journal of diabetes and its complications.

[16]  Z. Berneman,et al.  Platelet Prothrombinase Activity, a Final Pathway Platelet Procoagulant Activity, Is Overexpressed in Type 1 Diabetes: No Relationship With Mean Platelet Volume or Background Retinopathy , 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[17]  R. Testa,et al.  Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[18]  S. Greene,et al.  Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with Type 1 diabetes with no clinical vascular disease , 1999, Diabetes/metabolism research and reviews.

[19]  G. Lowe,et al.  The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh Artery Study , 1999, British journal of haematology.

[20]  M. Nishikawa,et al.  Significance of Platelet-Derived Microparticles and Activated Platelets in Diabetic Nephropathy , 1999, Nephron.

[21]  M. Nishikawa,et al.  Effect of Cilostazol on Soluble Adhesion Molecules and Platelet-derived Microparticles in Patients with Diabetes , 1998, Thrombosis and Haemostasis.

[22]  A. Desfaits,et al.  Normalization of Plasma Lipid Peroxides, Monocyte Adhesion, and Tumor Necrosis Factor-α Production in NIDDM Patients After Gliclazide Treatment , 1998, Diabetes Care.

[23]  G. Rotolo,et al.  Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients. , 1997, Metabolism: clinical and experimental.

[24]  B. Sandhagen,et al.  Haemorheology in insulin‐dependent diabetes is still normal five years after onset of the disease , 1997, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[25]  L. Bent-Hansen.  Whole body capillary exchange of albumin. Alterations in diabetic microangiopathy. , 1997, Danish medical bulletin.

[26]  M. Blombäck,et al.  Altered properties of the fibrin gel structure in patients with IDDM , 1996, Diabetologia.

[27]  M. Sata,et al.  Protein C activation in NIDDM patients , 1996, Diabetologia.

[28]  P. Rossing,et al.  Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy , 1996 .

[29]  A. Shore,et al.  Diabetic angiopathy: tracking down the culprits. , 1996, Journal of diabetes and its complications.

[30]  M. Pirisi,et al.  Post-meal coagulation activation in diabetes mellitus: the effect of acarbose , 1996, Diabetologia.

[31]  P. Grant.  The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes , 1996, Diabetes Care.

[32]  M. Blombäck,et al.  The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[33]  P. Grant,et al.  Plasminogen Activator Inhibitor-1 (PAI-1) Promoter Polymorphism and Coronary Artery Disease in Non-Insulin-Dependent Diabetes , 1995, Thrombosis and Haemostasis.

[34]  P. Moghetti,et al.  Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control , 1995, Diabetologia.

[35]  D. Dhall,et al.  Effects of gliclazide on fibrin network. , 1994, Journal of diabetes and its complications.

[36]  P. Pietschmann,et al.  Haemostatic Abnormalities Persist Despite Glycaemic Improvement by Insulin Therapy in Lean Type 2 Diabetic Patients , 1994, Thrombosis and Haemostasis.

[37]  E. Falleti,et al.  Fibrinogen Plasma Levels as a Marker of Thrombin Activation in Diabetes , 1994, Diabetes.

[38]  P. Vague,et al.  Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. , 1993, The Journal of clinical investigation.

[39]  J. Yudkin,et al.  Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups , 1993, Diabetes Care.

[40]  A. Azhar,et al.  Studies on fibrin network structure in human plasma. Part II--Clinical application: diabetes and antidiabetic drugs. , 1991, Thrombosis research.

[41]  M. Alessi,et al.  Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis , 1991, Diabetologia.

[42]  P. Grant,et al.  Metformin Causes a Reduction in Basal and Post‐venous Occlusion Plasminogen Activator Inhibitor‐1 in Type 2 Diabetic Patients , 1991, Diabetic medicine : a journal of the British Diabetic Association.

[43]  Y. Komiyama,et al.  Increased accumulation of nonenzymatically glycated fibrinogen in the renal cortex in rats. , 1990, Thrombosis research.

[44]  P. Vague,et al.  Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin , 1989, Thrombosis and Haemostasis.

[45]  M. Alessi,et al.  Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects , 1987, Thrombosis and Haemostasis.

[46]  A. Cerami,et al.  Nonenzymatic Glycosylation Reduces the Susceptibility of Fibrin to Degradation by Plasmin , 1983, Diabetes.

[47]  Limei Hu,et al.  Impact of diabetes-associated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. , 2002, The Journal of clinical endocrinology and metabolism.

[48]  J. Weisel,et al.  The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. , 2002, Diabetes.

[49]  T. Vrijkotte,et al.  Covariance of metabolic and hemostatic risk indicators in men and women , 2001 .

[50]  Ametov As,et al.  The use of ticlid in diabetic retinopathy , 1997 .

[51]  C. Kluft.  Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAT-1): Conditions and therapeutic targets , 1994 .

[52]  H J Bilo,et al.  Blood and plasma viscosity in diabetes: possible contribution to late organ complications? , 1992, Diabetes research.

[53]  E. Bierman.  Atherogenesis in diabetes , 1992 .

[54]  L. Bent-Hansen.  Whole body capillary exchange of albumin. , 1991, Acta physiologica Scandinavica. Supplementum.

[55]  H. Tindall,et al.  Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.